Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study
- PMID: 25887136
- DOI: 10.1016/j.rmed.2015.03.008
Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study
Abstract
Introduction: Severe community-acquired pneumonia is defined as community-acquired pneumonia that requires intensive medical care. Mortality in these patients is still high depending on time and admission. Since bad outcomes may occur despite antibiotic therapy to treat severe community-acquired pneumonia, the focus has shifted to targeting the host response. The CIGMA Study examines the safety and efficacy of the novel IgM-enriched immunoglobulin preparation BT086 when added to standard of care treatment.
Methods/design: The aim of this multicentre, randomised, placebo-controlled, double-blind, parallel-group, adaptive group-sequential phase II study is to determine the efficacy and safety of BT086, an IgM-enriched immunoglobulin preparation, as an adjunctive treatment in mechanically-ventilated patients with severe community-acquired pneumonia. The increase of ventilator-free days is the primary endpoint in this study. For this trial, ventilator-free days are defined as the number of days between successful extubation from endotracheal ventilation and day 28 after enrolment of the patient into the study. Two interim analyses were considered for this study.
Discussion: Several novel agents for treatment of sepsis have been evaluated in the last two decades; however, none has significantly reduced mortality rates. Failure was attributed to the heterogeneity of septic patients or sepsis. Severe community-acquired pneumonia was chosen as the indication for this study to increase homogeneity within this patient population.
Trial registration: EUDRACT 2010-022380-35.
Keywords: Adjunctive therapy; BT086; IgM-enriched immunoglobulins; Mechanically-ventilated; Severe community-acquired pneumonia; Ventilator-free days.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).Intensive Care Med. 2018 Apr;44(4):438-448. doi: 10.1007/s00134-018-5143-7. Epub 2018 Apr 9. Intensive Care Med. 2018. PMID: 29632995 Free PMC article. Clinical Trial.
-
Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.BMJ. 2006 Jun 10;332(7554):1355. doi: 10.1136/bmj.332.7554.1355. BMJ. 2006. PMID: 16763247 Free PMC article. Clinical Trial.
-
Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.PLoS One. 2017 Jun 15;12(6):e0178022. doi: 10.1371/journal.pone.0178022. eCollection 2017. PLoS One. 2017. PMID: 28617807 Free PMC article. Clinical Trial.
-
Is it possible to blind a trial for community-acquired pneumonia?Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S210-5. doi: 10.1086/591428. Clin Infect Dis. 2008. PMID: 18986292 Review.
-
The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia.Clin Chest Med. 2011 Sep;32(3):491-505. doi: 10.1016/j.ccm.2011.06.002. Clin Chest Med. 2011. PMID: 21867818 Review.
Cited by
-
Clinical practice of sepsis-induced immunosuppression: Current immunotherapy and future options.Chin J Traumatol. 2024 Mar;27(2):63-70. doi: 10.1016/j.cjtee.2023.11.001. Epub 2023 Nov 8. Chin J Traumatol. 2024. PMID: 38040590 Free PMC article. Review.
-
Serum IgG levels and mortality in patients with severe sepsis and septic shock : The SBITS data.Med Klin Intensivmed Notfmed. 2017 Jun;112(5):462-470. doi: 10.1007/s00063-016-0220-6. Epub 2016 Sep 27. Med Klin Intensivmed Notfmed. 2017. PMID: 27677760 English.
-
New aspects in the management of pneumonia.Crit Care. 2016 Oct 1;20(1):267. doi: 10.1186/s13054-016-1442-y. Crit Care. 2016. PMID: 27716262 Free PMC article. Review.
-
Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients.PLoS One. 2018 Jan 25;13(1):e0191721. doi: 10.1371/journal.pone.0191721. eCollection 2018. PLoS One. 2018. PMID: 29370285 Free PMC article.
-
Anti-protein immunoglobulin M responses to pneumococcus are not associated with aging.Pneumonia (Nathan). 2018 Jun 5;10:5. doi: 10.1186/s41479-018-0048-3. eCollection 2018. Pneumonia (Nathan). 2018. PMID: 29992080 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials